A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

NCT00950638 | Completed Phase 1

• 1 other identifier: OPH2001
• Study Type: interventional
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).

Conditions

Dry Age-Related Macular Degeneration

Keywords

AMD

Outcome Measures

Primary Outcomes (1)

• Presence of any dose-limiting toxicity (DLT), safety endpoints include adverse events, vital signs, ophthalmic variables and outcomes

  1 year

Study Arms (2)

dose comparison

ACTIVE COMPARATOR

Drug: Avacincaptad Pegol

Dose comparison

ACTIVE COMPARATOR

Drug: Avacincaptad Pegol

Interventions

Avacincaptad Pegol DRUG

intravitreal injection

Also known as: Zimura (previous name), IZERVAY, ARC1905

Dose comparison; dose comparison

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Dry AMD (drusen and/or geographic atrophy) in both eyes

You may not qualify if:

• Any intraocular surgery or thermal laser within three (3) months of trial entry. Any prior thermal laser in the macular region, regardless of indication.
• Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past twelve (12) weeks.
• History of any of the following procedures: Posterior vitrectomy, filtering surgery (e.g. trabeculectomy), glaucoma drainage device, corneal transplant or retinal detachment.
• Any of the following underlying diseases including:
• Diabetic retinopathy
• History or evidence of severe cardiac disease (e.g., NYHA Functional Class III or IV ), history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within last 6 months, ventricular tachyarrythmias requiring ongoing treatment.
• History or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation.
• Clinically significant impaired renal (serum creatinine \>2.5 mg/dl or status post renal transplant or receiving dialysis) or hepatic function. Subjects with results outside these ranges may be enrolled in consultation with Ophthotech.
• Stroke (within 12 months of trial entry).
• Any major surgical procedure within one month of trial entry. Previous therapeutic radiation in the region of the study eye. Any treatment with an investigational agent in the past 60 days for any condition.
• Women who are pregnant or nursing. Known serious allergies to the fluorescein dye used in angiography or to the components of the ARC1905 formulation.

Sponsors & Collaborators

• Ophthotech Corporation: lead

Study Sites (1)

Ophthotech

New York, New York, United States

Location

Related Links

• Link to plain language summary of the study on the Trial Results Summaries website

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 30, 2009
• First Posted: August 3, 2009
• Study Start: July 16, 2009
• Primary Completion: March 24, 2011
• Study Completion: March 24, 2011
• Last Updated: March 10, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)